Literature DB >> 17005838

Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.

Ken B Waites1, Lynn B Duffy, Michael J Dowzicky.   

Abstract

The activities of tigecycline and comparators against isolates collected from 76 U.S. centers between January 2004 and September 2005 were assessed. Tigecycline MIC(90)s were < or =2 microg/ml for Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens, Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Streptococcus agalactiae.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17005838      PMCID： PMC1610085          DOI： 10.1128/AAC.00210-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  MRSA--what is it, and how do we deal with the problem?

Authors:  John F Barrett
Journal:  Expert Opin Ther Targets       Date:  2005-04       Impact factor: 6.902

2.  Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004).

Authors:  P R Rhomberg; T R Fritsche; H S Sader; R N Jones
Journal:  J Chemother       Date:  2005-10       Impact factor: 1.714

3.  In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.

Authors:  Patricia A Bradford; D Tasha Weaver-Sands; Peter J Petersen
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

Review 4.  Clinical impact and pathogenicity of Acinetobacter.

Authors:  M-L Joly-Guillou
Journal:  Clin Microbiol Infect       Date:  2005-11       Impact factor: 8.067

5.  In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  David L Paterson; Flávia Rossi; Fernando Baquero; Po-Ren Hsueh; Gail L Woods; Vilas Satishchandran; Theresa A Snyder; Charlotte M Harvey; Hedy Teppler; Mark J Dinubile; Joseph W Chow
Journal:  J Antimicrob Chemother       Date:  2005-04-22       Impact factor: 5.790

6.  Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection.

Authors:  Simona Bratu; Mohamad Mooty; Satyen Nichani; David Landman; Carl Gullans; Barbara Pettinato; Usha Karumudi; Pooja Tolaney; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.

Authors:  Simona Bratu; Pooja Tolaney; Usha Karumudi; John Quale; Mohamad Mooty; Satyen Nichani; David Landman
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

8.  Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.

Authors:  Helio S Sader; Ronald N Jones; Michael J Dowzicky; Thomas R Fritsche
Journal:  Diagn Microbiol Infect Dis       Date:  2005-07       Impact factor: 2.803

9.  Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

Authors:  Douglas J Biedenbach; Gary J Moet; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.803

10.  Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).

Authors:  Jennifer M Streit; Ronald N Jones; Helio S Sader; Thomas R Fritsche
Journal:  Int J Antimicrob Agents       Date:  2004-08       Impact factor: 5.283
View more
  16 in total

1.  Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges.

Authors:  Claudia Lengerke; Michael Haap; Frank Mayer; Lothar Kanz; Martina Kinzig; Ulrike Schumacher; Fritz Sörgel; Reimer Riessen
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

2.  New drugs to treat skin and soft tissue infections.

Authors:  Gary E Stein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

Review 3.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

4.  Hypermucoviscosity as a virulence factor in experimental Klebsiella pneumoniae endophthalmitis.

Authors:  Brandt J Wiskur; Jonathan J Hunt; Michelle C Callegan
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-27       Impact factor: 4.799

Review 5.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  Determination of susceptibility to fosfomycin and tigecycline of Enterobacteriaceae, particularly Escherichia coli isolates, producing extended-spectrum β-lactamases from multiple regional Canadian hospitals.

Authors:  Carlee Beuk; Christian Hill; Sue Whitehead; Edith Blondel-Hill; Ken Wagner; Naowarat Cheeptham
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

7.  Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California.

Authors:  Sonya C Valentine; Deisy Contreras; Stephanie Tan; Lilian J Real; Sheena Chu; H Howard Xu
Journal:  J Clin Microbiol       Date:  2008-06-04       Impact factor: 5.948

8.  In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest.

Authors:  Chris M Pillar; Deborah C Draghi; Michael J Dowzicky; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

9.  Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany.

Authors:  M Kresken; E Leitner; J Brauers; H K Geiss; E Halle; C von Eiff; G Peters; H Seifert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-21       Impact factor: 3.267

10.  Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.

Authors:  Jared L Crandon; Mary Anne Banevicius; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.